SOLENO THERAPEUT. DL-001 Asset Resilience Ratio
SOLENO THERAPEUT. DL-001 asset resilience ratio. SOLENO THERAPEUT. DL-001 (6XC) has an Asset Resilience Ratio of 41.74% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See SOLENO THERAPEUT. DL-001 defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of SOLENO THERAPEUT. DL-001 (2023–2025)
Asset resilience ratio of SOLENO THERAPEUT. DL-001 from 2023 to 2025. This chart shows how SOLENO THERAPEUT. DL-001's Asset Resilience Ratio has changed over time. Read how much debt does SOLENO THERAPEUT. DL-001 carry for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down SOLENO THERAPEUT. DL-001's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see SOLENO THERAPEUT. DL-001 total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €235.37 Million | 41.74% |
| Total Liquid Assets | €235.37 Million | 41.74% |
Asset Resilience Insights
- Very High Liquidity: SOLENO THERAPEUT. DL-001 maintains exceptional liquid asset reserves at 41.74% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
SOLENO THERAPEUT. DL-001 Industry Peers by Asset Resilience Ratio
Compare SOLENO THERAPEUT. DL-001's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513 |
Biotechnology | 35.16% |
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294 |
Biotechnology | 23.15% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Achieve Life Sciences Inc
F:SP4P |
Biotechnology | 3.60% |
SOLENO THERAPEUT. DL-001 Asset Resilience Ratio by Year (2023–2025)
SOLENO THERAPEUT. DL-001 asset resilience ratio by year from 2023 to 2025. The table below shows the annual Asset Resilience Ratio data for SOLENO THERAPEUT. DL-001.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 41.74% | €235.37 Million ≈ $275.17 Million |
€563.83 Million ≈ $659.18 Million |
-19.74pp |
| 2024-12-31 | 61.49% | €203.51 Million ≈ $237.92 Million |
€330.97 Million ≈ $386.94 Million |
-- |
| 2023-12-31 | 0.00% | €0.00 ≈ $0.00 |
€180.69 Million ≈ $211.25 Million |
-- |
About SOLENO THERAPEUT. DL-001
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeut… Read more